Final FDA Guidance Gives Sponsors More Flexibility In Using Latest Industry Standards For Biologics Submissions
Executive Summary
FDA’s biologics center has issued final guidance to sponsors on acceptable practices for using industry standards in developing regulatory submissions for new biologics and drugs.
You may also be interested in...
US FDA Pressing Industry To Use Standards For Cell and Gene Therapies
A US FDA official is exhorting the biopharmaceutical industry to adopt standards to help in developing new cell and gene therapy products, yet this may pose difficulties as there is a lack of standards in this space, particularly in areas such as cell viability, chain of identity and viral vector gene quantification.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.